Navigation Links
ARIUS announces second quarter fiscal 2008 financial results

Laureate Pharma Inc. for cGMP manufacturing of humanized

antibody for Phase 1 clinical supply. A cell line producing the

humanized anti-Trop-2 antibody was successfully transferred to


- Preparing for a pre-IND meeting with the FDA.

- ARIUS intends to have clinical trials' materials prepared in the

fourth quarter of 2008 and then a Phase I IND application is expected

to be filed and human clinical trials commenced.

CD59 Complement Inhibitor Program

- Presented a CD59-focused poster at AACR Annual Meeting.

- Generated a cell line producing humanized CD59 antibody that

successfully retained binding characteristics and potent in vivo


- Preparing to perform preclinical toxicology studies planned for 2008

in preparation for a Pre-IND meeting with the FDA and filing a

Phase I IND application.

CD9 Cancer Stem Cell Program

- Presented a CD9-focused poster at AACR Annual Meeting.

- Presented positive findings demonstrating the ability of the lead

anti-CD9 antibody to kill cancer stem cells in an in vivo model using

cells from human leukemia patients at the American Association of

Cancer Research Special Conference on Cancer Stem Cells in the first

quarter of 2008.

CD63 Antibody Program

- Licensed to Genentech, Inc. in March 2006, the CD63 program continues

to advance in preclinical studies in a variety of cancer indications

as part of a program to move the lead antibody towards the clinic.

Takeda Collaboration

- Discovered and delivered novel antibodies to Takeda. Under the terms

of the research collaboration agreement, ARIUS has successfully met

its obligations to date and has received all scheduled research

payments from Takeda.

Additional Product Updates

- Current

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results for ... complete 2014 second quarter financial statements and MD&A have been filed on ... 30, , Six-months ended June 30, ( in CDN$,000 except ... , 2014 , 2013 Revenue , 2,459 ... profit , 56 , 1,485 , 385 ...
(Date:8/22/2014)... have discovered how the receptors responsible for contractions in ... new study, published today in The FASEB Journal ... regulates the cycle of all cells in the body. ... biological clock and its control are weakened in ageing ... physiology and ageing. , While currently much ...
(Date:8/22/2014)... (August 22nd), in the scientific journal PLoS ... establish the effect of serotonin on sensitivity to ... optical techniques., "Serotonin is a small molecule known ... brain functions, from the control of sleep and ... This neurotransmitter is also popularly thought to contribute ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2From happiness to pain: Understanding serotonin's function 2
... Third Wave Technologies Inc. (Nasdaq: TWTI) today announced ... assays to RIKEN in Japan for use in various large ... Wave has been supplying its Invader SNP assays to Dr. ... Medicine at RIKEN, director of the Genome Center ...
... hit the road , ,MILWAUKEE - Ask any successful ... and you will get one answer: SALES. Despite this, sales ... in business school curricula today. What They Dont Teach You ... the Kellogg Alumni Club of Chicago titled Creating, Growing and ...
... between U.S. white collar workers and those in India is ... ,IT Manager ,U.S: $55,000 ,India: $8,500 , ,Accountant ,U.S.: $41,000 ... States were almost solely in the manufacturing sector, as more ... other Latin American countries to cut costs. Not to mention ...
Cached Biology Technology:Sales Strategies for the High-Tech Entrepreneur 2Sales Strategies for the High-Tech Entrepreneur 3Sales Strategies for the High-Tech Entrepreneur 4Sales Strategies for the High-Tech Entrepreneur 5Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 2Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 3
(Date:8/22/2014)... , August 22, 2014 /PRNewswire/ ... ) has announced the addition ... America 2014-2018"  report to their offering.  ... , ,Biometrics is a technology that ... based on their physical or behavioral ...
(Date:8/22/2014)... leading source of information for businesses and professionals, has ... in its 2014 list of "some of the best ... the list, the company analyzed citation data over 11 ... had enormous impact. , The following UC Riverside researchers ... greatest number of highly cited papers in one of ...
(Date:8/22/2014)... Research presented at the 29th Annual International Papillomavirus ... Hera Therapeutics Inc. combats three types of human ... of all cervical cancer. , When tested in ... replication of HPV-16, HPV-18 and HPV-11 cells, according ... Ph.D., who presented the findings at the Seattle ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... tap the vast, unexplored reaches of the earth,s microbial ... DOE Joint Genome Institute (DOE JGI) has announced its ... undertake in the coming year. The 44 projects, culled ... Program (CSP), represent over 60 billion nucleotides of data ...
... in Spanish . Most of the functions ... proteins, which recognise their binding partner by affinity features localized ... however, the most complicated to study from the perspective of ... interaction is brief and occurs through a large section of ...
... trials to find a successful vaccine against footrot in ... funding of $663,000 from Australian Wool Innovation (AWI) ... at Monash University,s Australian Research Council Centre of Excellence ... of Sydney. Chief investigator Professor Julian Rood said ...
Cached Biology News:US Department of Energy Joint Genome Institute announces new genome sequencing projects 2US Department of Energy Joint Genome Institute announces new genome sequencing projects 3US Department of Energy Joint Genome Institute announces new genome sequencing projects 4US Department of Energy Joint Genome Institute announces new genome sequencing projects 5US Department of Energy Joint Genome Institute announces new genome sequencing projects 6US Department of Energy Joint Genome Institute announces new genome sequencing projects 7Scientists reveal the key mechanisms for affinity between transient binding proteins 2Footrot vaccine closer than ever 2
... • Small design specifically for western blots ... are specifically designed for staining western blots. ... 25 mm) of the disposable tray requires ... significant cost savings to the user. Pour ...
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
Biology Products: